Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients with relapsed or refractory multiple myeloma: Subgroup analysis of POLLUX and CASTOR

Saad Z. Usmani, MD
Levine Cancer Institute
Carolinas HealthCare System
Charlotte, NC

Background: Daratumumab (D) plus lenalidomide and dexamethasone (Rd; POLLUX) or with bortezomib and dexamethasone (Vd; CASTOR) demonstrated prolonged PFS and tolerability compared with Rd and Vd alone, respectively, in RRMM pts. We examined the safety and efficacy profiles of DRd and DVd in elderly (≥75 y) pts from these phase 3 studies. 

Conclusions: The safety and efficacy profiles in elderly pts were generally comparable with the overall population in each study.

Author(s): Maria-Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Ludek Pour, Katja C. Weisel, Michele Cavo, Jacob Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Zafar Usmani, Sung-Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jordan Mark Schecter, Kaida Wu, Xiang Qin, David Soong, Meletios A. Dimopoulos

Clinical trial information: NCT02136134 and NCT02076009